实用临床医药杂志2024,Vol.28Issue(16) :136-141.DOI:10.7619/jcmp.20241351

循环肿瘤DNA在早期乳腺癌分子检测中的研究进展

Research progress of circulating tumor DNA in molecular detection of early breast cancer

石钰 徐澍
实用临床医药杂志2024,Vol.28Issue(16) :136-141.DOI:10.7619/jcmp.20241351

循环肿瘤DNA在早期乳腺癌分子检测中的研究进展

Research progress of circulating tumor DNA in molecular detection of early breast cancer

石钰 1徐澍2
扫码查看

作者信息

  • 1. 贵州医科大学临床医学院,贵州贵阳,550000
  • 2. 贵州医科大学临床医学院,贵州贵阳,550000;贵州医科大学附属医院病理科,贵州贵阳,550000
  • 折叠

摘要

通过常规检查方法(钼靶摄片、CT、超声)早期发现乳腺癌(BRCA)存在一定程度的局限,而液体活检技术在BRCA患者中的早期诊断优势日益显著.循环肿瘤DNA(ctDNA)是存在于体液中的部分游离于细胞外的DNA.ctDNA是以液体活检技术为基础的筛选新型肿瘤标志物的新思路,并有助于早期乳腺癌的临床决策.本研究就ctDNA的生物学特性、检测方法在早期BRCA诊治中的应用进行探讨,并展望ctDNA的未来研究方向.

Abstract

Breast cancer(BRCA)is the most common malignant tumor in the world and the leading cause of death in female patients.In addition,early detection of BRCA by conventional screening methods(mammography,CT,ultrasound)is limited to a certain extent,and liquid biopsy technology has become increasingly advantageous for the early diagnosis of BRCA patients.Circulat-ing Tumor DNA(ctDNA)is a partially free extracellular DNA present in body fluids.The ctDNA is a new idea for screening novel tumor markers based on liquid biopsy technology and helps in clinical decision-making for early breast cancer.In this paper,we discussed the biological properties of ctD-NA,detection methods,and its application in the diagnosis and treatment of early BRCA,and we al-so look forward to the future research direction of ctDNA.

关键词

早期乳腺癌/循环肿瘤DNA/液体活检/生物标志物

Key words

early breast cancer/circulating tumor DNA/liquid biopsy/biomarkers

引用本文复制引用

基金项目

贵州医科大学国家自然科学基金培育项目(I-2020-18)

出版年

2024
实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
参考文献量1
段落导航相关论文